

CITATION REPORT

List of articles citing

An Update on Current Therapeutic Drugs Treating COVID-19

DOI: 10.1007/s40495-020-00216-7

Current Pharmacology Reports, 2020, 6, 1-15.

Source: <https://exaly.com/paper-pdf/76642079/citation-report.pdf>

Version: 2024-04-20

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
374	Effective Immune Functions of Micronutrients against SARS-CoV-2. 2020 , 12,		20
373	The emergence of COVID-19 as a global pandemic: Understanding the epidemiology, immune response and potential therapeutic targets of SARS-CoV-2. 2020 , 179, 85-100		47
372	Curcumin, a traditional spice component, can hold the promise against COVID-19?. 2020 , 886, 173551		52
371	"Compliance of the Indian National Task Force guidelines for COVID-19 recommendation by Indian doctors - A survey". <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2020 , 14, 1413-1418 ^{8,9}		2
370	Serum Levels of Vitamin C and Vitamin D in a Cohort of Critically Ill COVID-19 Patients of a North American Community Hospital Intensive Care Unit in May 2020: A Pilot Study. 2020 , 8, 100064		59
369	Can Non-steroidal Anti-inflammatory Drugs Affect the Interaction Between Receptor Binding Domain of SARS-COV-2 Spike and the Human ACE2 Receptor? A Computational Biophysical Study. 2020 , 8,		6
368	Inflammation as a Driver of Prostate Cancer Metastasis and Therapeutic Resistance. 2020 , 12,		29
367	Targeting Proteases for Treating COVID-19. 2020 , 19, 4316-4326		36
366	Rapamycin as a potential repurpose drug candidate for the treatment of COVID-19. 2020 , 331, 109282		33
365	Whole genome sequencing and phylogenetic classification of Tunisian SARS-CoV-2 strains from patients of the Military Hospital in Tunis. 2020 , 56, 767-771		3
364	Recent Advancements in the Diagnosis, Prevention, and Prospective Drug Therapy of COVID-19. 2020 , 8, 384		7
363	The Natural History, Pathobiology, and Clinical Manifestations of SARS-CoV-2 Infections. 2020 , 15, 359-386		199
362	Immune response in COVID-19: A review. 2020 , 13, 1619-1629		143
361	An updated insight into the molecular pathogenesis, secondary complications and potential therapeutics of COVID-19 pandemic. 2020 , 257, 118105		30
360	Volatile molecules for COVID-19: A possible pharmacological strategy?. 2020 , 81, 950		9
359	Interaction of synthetic antimicrobial peptides of the Hylin a1 family with models of eukaryotic structures: Zwitterionic membranes and DNA. 2020 , 24, 100827		2
358	First Report of Tocilizumab Use in a Cohort of Latin American Patients Hospitalized for Severe COVID-19 Pneumonia. 2020 , 7, 596916		2

357	Ophthalmic complaints in face-mask wearing: prevalence, treatment, and prevention with a potential protective effect against SARS-CoV-2. 2020 , 34, 1323-1335		6
356	Modelling the structural and reactivity landscapes of tucatinib with special reference to its wavefunction-dependent properties and screening for potential antiviral activity. 2020 , 26, 341		17
355	Puzzling out the COVID-19: Therapy targeting HLA-G and HLA-E. 2020 , 81, 697-701		11
354	Engineering a novel subunit vaccine against SARS-CoV-2 by exploring immunoinformatics approach. 2020 , 21, 100478		11
353	Camostat Mesylate May Reduce Severity of Coronavirus Disease 2019 Sepsis: A First Observation. 2020 , 2, e0284		25
352	Multiple Effects of Ascorbic Acid against Chronic Diseases: Updated Evidence from Preclinical and Clinical Studies. 2020 , 9,		14
351	Association between early treatment with Qingfei Paidu decoction and favorable clinical outcomes in patients with COVID-19: A retrospective multicenter cohort study. 2020 , 161, 105290		33
350	Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. 2020 , 146, 111805		18
349	The Flood of COVID-19 Publications: a Word of Caution. 2020 , 2, 1-3		2
348	Impact of Hydroxychloroquine on Mortality in Hospitalized Patients with COVID-19: Systematic Review and Meta-Analysis. 2020 , 8,		4
347	A comprehensive review of COVID-19 characteristics. 2020 , 22, 19		170
346	COVID-19: A review of the proposed pharmacological treatments. 2020 , 886, 173451		54
345	Treatment of COVID-19: Perspective on Convalescent Plasma Transfusion. 2020 , 7, 435		5
344	Mechanisms Underlying Potential Therapeutic Approaches for COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 1841	8.4	6
343	Coronavirus Disease-2019 (COVID-19): An Updated Review. 2020 , 70, 389-400		25
342	Current status and strategic possibilities on potential use of combinational drug therapy against COVID-19 caused by SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 39, 6828-6841	3.6	24
341	Risks to the community pharmacists and pharmacy personnel during COVID-19 pandemic: perspectives from a low-income country. 2020 , 13, 42		9
340	Food and COVID-19: Preventive/Co-therapeutic Strategies Explored by Current Clinical Trials and in Silico Studies. 2020 , 9,		18

339	Plants Metabolites: Possibility of Natural Therapeutics Against the COVID-19 Pandemic. 2020 , 7, 444	53
338	Cancer Management during COVID-19 Pandemic: Is Immune Checkpoint Inhibitors-Based Immunotherapy Harmful or Beneficial?. 2020 , 12,	52
337	Analysis of Gender-Dependent Personal Protective Behaviors in a National Sample: Polish Adolescents' COVID-19 Experience (PLACE-19) Study. 2020 , 17,	42
336	Is COVID-19 impacting plant science, and is plant science impacting COVID-19?. 2020 , 12, 769-772	1
335	Race to arsenal COVID-19 therapeutics: Current alarming status and future directions. 2020 , 332, 109298	5
334	Recent Advances in Pathophysiology, Drug Development and Future Perspectives of SARS-CoV-2. 2020 , 8, 580202	19
333	A 21st Century Evil: Immunopathology and New Therapies of COVID-19. <i>Frontiers in Immunology</i> , 2020 , 11, 562264	8.4 5
332	Study Design Characteristics and Pharmacological Mechanisms in International Clinical Trials Registry Platform: Registered Clinical Trials on Antiviral Drugs for COVID-19. 2020 , 14, 3803-3813	3
331	Role of IFN and Complements System: Innate Immunity in SARS-CoV-2. 2020 , 13, 507-518	14
330	structure modelling of SARS-CoV-2 Nsp13 helicase and Nsp14 and repurposing of FDA approved antiviral drugs as dual inhibitors. 2020 , 21, 100860	37
329	Important Pharmacogenetic Information for Drugs Prescribed During the SARS-CoV-2 Infection (COVID-19). 2020 , 13, 1023-1033	6
328	[SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. 2020 , 79, 686-691	5
327	Ketanserin as potential additive drug to improve V/Q mismatch in COVID-19?. 2020 , 24, 526	5
326	Immunotherapy for SARS-CoV-2: potential opportunities. 2020 , 20, 1111-1116	28
325	Favipiravir Use in COVID-19: Analysis of Suspected Adverse Drug Events Reported in the WHO Database. 2020 , 13, 4427-4438	26
324	Can Socioeconomic, Health, and Safety Data Explain the Spread of COVID-19 Outbreak on Brazilian Federative Units?. 2020 , 17,	6
323	Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update. 2020 , 7, 616527	7
322	Clinical Profile, Treatment and Predictors during the First COVID-19 Wave: A Population-Based Registry Analysis from Castile and Leon Hospitals. 2020 , 17,	6

321	Systemic mycoses: a potential alert for complications in COVID-19 patients. 2020 , 15, 1405-1413	18
320	Geranii Herba as a Potential Inhibitor of SARS-CoV-2 Main 3CL, Spike RBD, and Regulation of Unfolded Protein Response: An In Silico Approach. 2020 , 9,	13
319	Drug repurposing of nitazoxanide: can it be an effective therapy for COVID-19?. <i>Journal of Genetic Engineering and Biotechnology</i> , 2020 , 18, 35	3.1 39
318	Excess Ascorbate is a Chemical Stress Agent against Proteins and Cells. 2020 , 13,	2
317	Management of Neovascular Age-Related Macular Degeneration during the COVID-19 Pandemic. 2020 , 4, 757-759	14
316	Higher prevalence of asymptomatic or mild COVID-19 in children, claims and clues. 2020 , 92, 2257-2259	14
315	Covid-19: a comprehensive review of a formidable foe and the road ahead. 2020 , 14, 869-879	9
314	Repurposing minocycline for COVID-19 management: mechanisms, opportunities, and challenges. 2020 , 18, 997-1003	13
313	Tuberculosis sepsis after tocilizumab treatment. 2020 , 26, 1493-1494	5
312	Endothelial dysfunction in Coronavirus disease 2019 (COVID-19): Gender and age influences. 2020 , 144, 110015	42
311	Drug targets for COVID-19 therapeutics: Ongoing global efforts. 2020 , 45, 1	54
310	Targeting inflammation and cytokine storm in COVID-19. 2020 , 159, 105051	31
309	Sex differences in SARS-CoV-2 infection rates and the potential link to prostate cancer. 2020 , 3, 374	77
308	Factors Associated With Pulmonary Embolism Among Coronavirus Disease 2019 Acute Respiratory Distress Syndrome: A Multicenter Study Among 375 Patients. 2020 , 2, e0166	17
307	Plasma-based COVID-19 treatments in low- and middle-income nations pose a high risk of an HIV epidemic. 2020 , 5, 58	12
306	A proposed strategy for management of immunosuppression in heart transplant patients with COVID-19. 2020 , 34, e14032	9
305	Targeting the NO-cGMP-PDE5 pathway in COVID-19 infection. The DEDALO project. 2021 , 9, 33-38	26
304	Potential role of interferons in treating COVID-19 patients. 2021 , 90, 107171	36

303	Fighting the War Against COVID-19 via Cell-Based Regenerative Medicine: Lessons Learned from 1918 Spanish Flu and Other Previous Pandemics. 2021 , 17, 9-32	5
302	Synthesis, characterization and computational study on potential inhibitory action of novel azo imidazole derivatives against COVID-19 main protease (M: 6LU7). 2021 , 1225, 129230	15
301	Severe acute respiratory syndrome-coronavirus-2 spike (S) protein based vaccine candidates: State of the art and future prospects. 2021 , 31, e2183	19
300	Computational Intelligence Methods in COVID-19: Surveillance, Prevention, Prediction and Diagnosis. 2021 ,	
299	Review on therapeutic targets for COVID-19: insights from cytokine storm. 2021 , 97, 391-398	11
298	CB2 receptor-selective agonists as candidates for targeting infection, inflammation, and immunity in SARS-CoV-2 infections. 2021 , 82, 7-11	8
297	evaluation of flavonoids as effective antiviral agents on the spike glycoprotein of SARS-CoV-2. 2021 , 28, 1040-1051	30
296	Drug repurposing for the treatment of COVID-19: Pharmacological aspects and synthetic approaches. 2021 , 106, 104488	14
295	Therapeutic drugs for SARS-CoV-2 treatment: Current state and perspective. 2021 , 90, 107228	12
294	CETSA MS Profiling for a Comparative Assessment of FDA-Approved Antivirals Repurposed for COVID-19 Therapy Identifies TRIP13 as a Remdesivir Off-Target. 2021 , 26, 336-344	6
293	Sex differences in COVID-19: the role of androgens in disease severity and progression. 2021 , 71, 3-8	49
292	Structural investigations, quantum mechanical studies on proton and metal affinity and biological activity predictions of selpercatinib. 2021 , 325, 114765	10
291	COVID-19 pandemic: mechanism, diagnosis, and treatment. 2021 , 96, 299-308	9
290	A retrospective comparison of drugs against COVID-19. 2021 , 294, 198262	2
289	A Revisit to the Research Updates of Drugs, Vaccines, and Bioinformatics Approaches in Combating COVID-19 Pandemic. 2020 , 7, 585899	6
288	Can limonene be a possible candidate for evaluation as an agent or adjuvant against infection, immunity, and inflammation in COVID-19?. 2021 , 7, e05703	14
287	Thirty-day readmission rate of COVID-19 patients discharged from a tertiary care university hospital in Turkey: an observational, single-center study. 2021 , 33,	19
286	Regen med therapeutic opportunities for fighting COVID-19. 2021 , 10, 5-13	9

285 Coronavirus disease 2019 - Emerging and future challenges for oral health care professionals. **2021**,

284 COVID-19: What Should the General Practitioner Know?. **2021**, 16, 43-56

4

283 The Current Understanding and Potential Therapeutic Options to Combat COVID-19.

282 COVID-19 Treatment: Drug Safety Prior to Conception and During Pregnancy and Breastfeeding. **2021**, 81, 46-60

2

281 Introduction to the Virus and Its Infection Stages. **2021**, 1-26

280 Prospecting for to treat COVID-19 via molecular docking models of the SARS-CoV-2. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-10

3.6 8

279 Review of pharmacologic and immunologic agents in the management of COVID-19. **2021**, 3, 148-155

3

278 Immunomodulatory and anti-cytokine therapeutic potential of curcumin and its derivatives for treating COVID-19 - a computational modeling. *Journal of Biomolecular Structure and Dynamics*, **2021**, 1-16

3.6 13

277 The inhibitory effects of PGG and EGCG against the SARS-CoV-2 3C-like protease. **2021**, 591, 130-130

21

276 Clinical characteristics of patients infected with SARS-CoV-2 in North Wollo Zone, North-East Ethiopia. **2021**, 38, 217

2

275 COVID-19: can we treat the mother without harming her baby?. **2021**, 1-11

2

274 Potential inhibitors of SARS-CoV-2 (COVID 19) proteases PL and M/ 3CL: molecular docking and simulation studies of three pertinent medicinal plant natural components. **2021**, 2, 100038

8

273 Nanotechnology Enabled Solutions to Combat Covid-19: Prevention, Treatment and Diagnosis. **2021**,

1

272 Knowledge, attitude, and practice of university students toward COVID-19 in Sudan: An online-based cross-sectional study. **2021**, 19, 70

1

271 Repurposing existing drugs: identification of SARS-CoV-2 3C-like protease inhibitors. **2021**, 36, 147-153

14

270 A Recent Achievement in the Discovery and Development of Vaccines and Therapeutic Agents in the Race for COVID-19 Protection and Treatment. **2021**, 26, 2515690X211003727

1

269 Data and Network Analytics for COVID-19 ICU Patients: A Case Study for a Spanish Hospital. **2021**, 25, 4340-4353

2

268 Ongoing Clinical Trials and the Potential Therapeutics for COVID-19 Treatment. **2021**, 27-89

267	Bioinformatic Approaches for Identification of Potential Repurposable Drugs in COVID-19. 2021 , 11, 13-22		0
266	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent. 2021 , 28, 202-209		46
265	Prediction of Anti-COVID 19 Therapeutic Power of Medicinal Moroccan Plants Using Molecular Docking. 2021 , 15, 11779322211009199		5
264	The use of laboratory parameters and computed tomography score to determine intensive care unit requirement in COVID-19. 2021 , 46, 157-166		3
263	COVID-19 Impairs Immune Response to. <i>Frontiers in Immunology</i> , 2021 , 12, 640644	8.4	18
262	Knowledge and Practice Toward Prevention of SARS-CoV-2 Among Healthcare Workers at Delghi Primary Hospital During a Massive Test Campaign in Northwest Gondar, Ethiopia: Institution-Based Descriptive Cross-Sectional Survey. 2021 , 14, 381-390		6
261	Can be a potential candidate to target immunity, inflammation, and infection - The trinity of coronavirus disease 2019. 2021 , 7, e05990		6
260	Retrained Generic Antibodies Can Recognize SARS-CoV-2. 2021 , 12, 1438-1442		1
259	Case Discussion and Literature Review: Cancer Immunotherapy, Severe Immune-Related Adverse Events, Multi-Inflammatory Syndrome, and Severe Acute Respiratory Syndrome Coronavirus 2. 2021 , 11, 625707		5
258	Clinical Efficiency and Safety of Riamilovir for Treating Patients with SARS-CoV-2 Infection. 2021 , 65, 16-21		6
257	Plant-Derived Food Grade Substances (PDFGS) Active Against Respiratory Viruses: A Systematic Review of Non-clinical Studies. 2021 , 8, 606782		3
256	Carvacrol, a Plant Metabolite Targeting Viral Protease (M) and ACE2 in Host Cells Can Be a Possible Candidate for COVID-19. 2020 , 11, 601335		15
255	Pharmacogenomics and COVID-19: clinical implications of human genome interactions with repurposed drugs. 2021 , 21, 275-284		11
254	Artificially expanded genetic information systems (AEGISs) as potent inhibitors of the RNA-dependent RNA polymerase of the SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-17	3.6	6
253	Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial. 2021 , 26, 20		42
252	Excited-state electronic properties, structural studies, noncovalent interactions, and inhibition of the novel severe acute respiratory syndrome coronavirus 2 proteins in Ripretinib by first-principle simulations. 2021 , 324, 115134		13
251	Efficacy and Safety of New and Emerging Drugs for COVID-19: Favipiravir and Dexamethasone. <i>Current Pharmacology Reports</i> , 2021 , 7, 1-6	5.5	6
250	A Journey From SARS-CoV-2 to COVID-19 and Beyond: A Comprehensive Insight of Epidemiology, Diagnosis, Pathogenesis, and Overview of the Progress into Its Therapeutic Management. <i>Frontiers in Pharmacology</i> , 2021 , 12, 576448	5.6	5

249	Modeling of SARS-CoV-2 Treatment Effects for Informed Drug Repurposing. <i>Frontiers in Pharmacology</i> , 2021 , 12, 625678	5.6	7
248	The situation of small molecules targeting key proteins to combat SARS-CoV-2: Synthesis, metabolic pathway, mechanism of action, and potential therapeutic applications. 2021 ,		0
247	Clinical Management of Hypertension, Inflammation and Thrombosis in Hospitalized COVID-19 Patients: Impact on Survival and Concerns. 2021 , 10,		5
246	Knowledge, attitude and practices of COVID-19 among medical laboratory professionals in Zambia. 2021 , 10, 1403		4
245	Multiscale Simulations of SARS-CoV-2 3CL Protease Inhibition with Aldehyde Derivatives. Role of Protein and Inhibitor Conformational Changes in the Reaction Mechanism. 2021 , 11, 4157-4168		18
244	Nanomedicine Technology and COVID-19 Outbreak: Applications and Challenges. 2021 , 06, 161-174		5
243	The study of antiviral drugs targeting SARS-CoV-2 nucleocapsid and spike proteins through large-scale compound repurposing. 2021 , 7, e06387		12
242	A review of Cameroonian medicinal plants with potentials for the management of the COVID-19 pandemic. 1		8
241	High Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Non-Covalent Inhibitor.		9
240	A review of novel coronavirus disease (COVID-19): based on genomic structure, phylogeny, current shreds of evidence, candidate vaccines, and drug repurposing. 2021 , 11, 198		8
239	Severe Respiratory Viral Infections: Epigenetic Mechanisms of Predisposition and the Possibilities of Epigenetically Targeted Therapy. 2021 , 7, 136-160		
238	Functional and Structural Characterization of SARS-Cov-2 Spike Protein: An Study. 2021 , 31, 213-222		2
237	The find of COVID-19 vaccine: Challenges and opportunities. 2021 , 14, 389-416		18
236	COVID-19 vaccines: The status and perspectives in delivery points of view. 2021 , 170, 1-25		127
235	Potency of Mesenchymal Stem Cell and Its Secretome in Treating COVID-19. 2021 , 1-12		5
234	In Vitro Assessment of the Antiviral Activity of Ketotifen, Indomethacin and Naproxen, Alone and in Combination, against SARS-CoV-2. 2021 , 13,		14
233	Insilico drug repurposing using FDA approved drugs against Membrane protein of SARS-CoV-2. 2021 , 110, 2346-2354		6
232	Present and future treatment strategies for coronavirus disease 2019. 2021 , 7, 84		7

231	Pharmacological Modulators of Autophagy as a Potential Strategy for the Treatment of COVID-19. 2021 , 22,	10
230	Identification of potential natural inhibitors of the receptor-binding domain of the SARS-CoV-2 spike protein using a computational docking approach. 2021 , 2021, 12	2
229	Drug Repurposing Approach, Potential Drugs, and Novel Drug Targets for COVID-19 Treatment. 2021 , 2021, 6631721	11
228	Computational drug screening against the SARS-CoV-2 Saudi Arabia isolates through a multiple-sequence alignment approach. 2021 , 28, 2502-2509	0
227	Treatment profiles and clinical outcomes of COVID-19 patients at private hospital in Jakarta. 2021 , 16, e0250147	11
226	A status report with critical analysis of research trends in exploring medicinal plants as antiviral: Let us dig into the history to predict the future. 2021 , 35, 4284-4296	0
225	A review on the clinical trials of repurposing therapeutic drugs, mechanisms and preventive measures against SARS-CoV-2. 2021 ,	
224	Polymer-based nano-therapies to combat COVID-19 related respiratory injury: progress, prospects, and challenges. 2021 , 32, 1219-1249	8
223	Antimicrobial peptides and other peptide-like therapeutics as promising candidates to combat SARS-CoV-2. 2021 , 19, 1205-1217	15
222	Role of phytoconstituents in the management of COVID-19. 2021 , 341, 109449	9
221	Antifibrotic Drugs for COVID-19: From Orphan Drugs to Blockbusters?. 2021 , 17, 8-12	
220	Current understanding on molecular drug targets and emerging treatment strategy for novel coronavirus-19. 2021 , 394, 1383-1402	0
219	An Examination of COVID-19 Medications' Effectiveness in Managing and Treating COVID-19 Patients: A Comparative Review. 2021 , 9,	1
218	Prevalence of COVID-19 and seroprevalence to SARS-CoV-2 in a rheumatologic patient population from a tertiary referral clinic in Israel. 2021 , 51, 682-690	0
217	Learning from crisis: repurposing to address grand challenges. 1-11	2
216	Existing Drugs Considered as Promising in COVID-19 Therapy. 2021 , 22,	9
215	Network pharmacology approach to decipher signaling pathways associated with target proteins of NSAIDs against COVID-19. 2021 , 11, 9606	16
214	Efficacy of Sofosbuvir plus Ledipasvir in Egyptian patients with COVID-19 compared to standard treatment: Randomized controlled trial.	2

213	Emergent Drug and Nutrition Interactions in COVID-19: A Comprehensive Narrative Review. 2021 , 13,		12
212	Epidemiology, pathogenesis, clinical presentations, diagnosis and treatment of COVID-19: a review of current evidence. 2021 , 14, 601-621		29
211	Mechanism involved in the pathogenesis and immune response against SARS-CoV-2 infection. 2021 , 32, 1-9		3
210	Review of a controversial treatment method in the fight against COVID-19 with the example of Algeria. 2021 , 45, 94		3
209	Remdesivir for coronavirus disease 2019 (COVID-19): a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. 2021 , 53, 691-699		8
208	Bioactivity, bioavailability, and gut microbiota transformations of dietary phenolic compounds: implications for COVID-19. 2021 , 97, 108787		14
207	Tocilizumab and COVID-19: a meta-analysis of 2120 patients with severe disease and implications for clinical trial methodologies. 2021 , 51, 890-897		11
206	The immune modulatory effects of umbilical cord-derived mesenchymal stromal cells in severe COVID-19 pneumonia. 2021 , 12, 316		4
205	Neurological Implications of COVID-19: Role of Redox Imbalance and Mitochondrial Dysfunction. 2021 , 58, 4575-4587		5
204	Therapeutic Effectiveness and Safety of Repurposing Drugs for the Treatment of COVID-19: Position Standing in 2021. <i>Frontiers in Pharmacology</i> , 2021 , 12, 659577	5.6	15
203	Coronavirus Disease 2019 (COVID-19): Origin, Impact, and Drug Development.		1
202	Efficacy of a Low Dose of Melatonin as an Adjunctive Therapy in Hospitalized Patients with COVID-19: A Randomized, Double-blind Clinical Trial. 2021 , 53, 79-79		24
201	In Vitro Assessment for Dose Preparation and Simulated Administration of Azithromycin Suspensions via Enteral Feeding Tubes. 001857872110242		
200	Therapeutic approaches to tackle COVID-19: An overview. 2021 , 8, 121-135		
199	Innovative Nanotechnology a Boon for Fight Against Pandemic COVID-19. 2021 , 3,		1
198	Mini-Review on SARS-CoV-2 Infection and Neurological Manifestations: A Perspective.. 2021 ,		2
197	The use of vitamin C in the intensive care unit during the COVID-19 pandemic. 2021 , 7, 425-431		1
196	Antiviral Therapeutic Approaches for SARS-CoV-2 Infection: A Systematic Review. 2021 , 14,		3

195	A new application of mTOR inhibitor drugs as potential therapeutic agents for COVID-19. 2021 ,		2
194	A dossier on COVID-19 chronicle. 2021 ,		2
193	Predicted occurrence, ecotoxicological risk and environmentally acquired resistance of antiviral drugs associated with COVID-19 in environmental waters. 2021 , 776, 145740		32
192	Effects of Immune System-Related Medications on COVID-19 Outcome in a Cohort of Iranian Patients: Preliminary Report of a Data Mining Study. 2021 , 2021, 9934134		0
191	Inhalation Delivery for the Treatment and Prevention of COVID-19 Infection. 2021 , 13,		13
190	Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2021 , 1-13	3.6	2
189	Glycyrrhizic Acid: A Natural Plant Ingredient as a Drug Candidate to Treat COVID-19. <i>Frontiers in Pharmacology</i> , 2021 , 12, 707205	5.6	3
188	Adverse Cardiovascular Effects of Anti-COVID-19 Drugs. <i>Frontiers in Pharmacology</i> , 2021 , 12, 699949	5.6	7
187	Targeting the SARS-CoV-2 3CL and NO/cGMP/PDE5 pathway in COVID-19: a commentary on PDE5 inhibitors. 2021 , 17, 765-768		3
186	Targeting Some Enzymes with Repurposing Approved Pharmaceutical Drugs for Expeditious Antiviral Approaches Against Newer Strains of COVID-19. 2021 , 22, 214		2
185	Antiviral drugs for coronavirus disease 2019 (COVID-19): a systematic review with network meta-analysis. 2021 , 1-12		3
184	Cannabinoid Type-2 Receptor Agonist, JWH133 May Be a Possible Candidate for Targeting Infection, Inflammation, and Immunity in COVID-19. 2021 , 1, 285-304		
183	Chloroquine and pyrimethamine inhibit the replication of human respiratory syncytial virus A. 2021 , 102,		0
182	-Dimethylation and -Functionalization of Amines Using Ru Nanoparticle Catalysts and Formaldehyde or Functional Aldehydes as the Carbon Source. 2021 , 6, 22504-22513		0
181	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. <i>Frontiers in Pharmacology</i> , 2021 , 12, 717757	5.6	9
180	Metal doped fullerene complexes as promising drug delivery materials against COVID-19. 2021 , 1-11		5
179	Reducing SARS-CoV-2 pathological protein activity with small molecules. 2021 , 11, 383-397		5
178	Human respiratory viral infections: Current status and future prospects of nanotechnology-based approaches for prophylaxis and treatment. 2021 , 278, 119561		3

177	COVID-19 Tanı Testleri, Tedavisindeki Akar ve Akar; Güncel Durum.		
176	Artificial Intelligence in Surveillance, Diagnosis, Drug Discovery and Vaccine Development against COVID-19. 2021 , 10,		9
175	Clinical Efficacy of Remdesivir and Favipiravir in the Treatment of Covid-19 Patients: Scenario So Far. 2021 ,		1
174	Phytomolecules Repurposed as Covid-19 Inhibitors: Opportunity and Challenges. 2021 , 78, 3620-3633		0
173	Dietary foods containing nitric oxide donors can be early curators of SARS-CoV-2 infection: A possible role in the immune system. 2021 , e13884		3
172	Non-competitive interactions between hydroxychloroquine and azithromycin: Systematic density functional, molecular dynamics, and docking calculations. 2021 , 777, 138745		2
171	Traditional Chinese Medicine is an Alternative Therapeutic Option for Treatment of Infections. <i>Frontiers in Pharmacology</i> , 2021 , 12, 737252	5.6	1
170	Energy and reactivity profile and proton affinity analysis of rimegepant with special reference to its potential activity against SARS-CoV-2 virus proteins using molecular dynamics. 2021 , 27, 276		4
169	Inhaled prostacyclin analogues in COVID-19 associated acute respiratory distress syndrome: scientific rationale. 2021 , 73, 82		0
168	Inhibition of the RNA-dependent RNA Polymerase of the SARS-CoV-2 by Short Peptide Inhibitors. 2021 , 167, 106012		2
167	Roles of existing drug and drug targets for COVID-19 management. 2021 , 11, 100103		3
166	A nanotechnological approach in the current therapy of COVID-19: model drug oseltamivir-phosphate loaded PLGA nanoparticles targeted with spike protein binder peptide of SARS-CoV-2. 2021 , 32,		4
165	Therapeutically effective covalent spike protein inhibitors in treatment of SARS-CoV-2. 2021 , 1-14		2
164	Chemical and Mechanical Actions of Drugs Active Group Used in COVID-19 Treatment. 229-237		
163	Liver injury in COVID-19: A Direct hit or Collateral damage?. 2021 ,		0
162	Screening of cryptogamic secondary metabolites as putative inhibitors of SARS-CoV-2 main protease and ribosomal binding domain of spike glycoprotein by molecular docking and molecular dynamics approaches. 2021 , 1240, 130506		4
161	Clinical Efficacy and Safety of Antiviral Drugs in the Extended Use against COVID-19: What We Know So Far. 2021 , 1, 252-284		7
160	Possibilities of daytime anxiolytics in the correction of residual neurological manifestations of COVID-19. 2021 , 50-60		3

159	Korean traditional foods as antiviral and respiratory disease prevention and treatments: A detailed review. 2021 , 116, 415-433	7
158	COVID-19, cytokines, inflammation, and spices: How are they related?. 2021 , 284, 119201	15
157	Potential bioactive compounds as SARS-CoV-2 inhibitors from extracts of the marine red alga (Rhodophyta) - A computational study.. 2021 , 14, 103393	4
156	Public willingness to adhere to COVID-19 precautionary measures in Sudan: an application of the Health Belief Model. 2021 , 39, 135	5
155	The History, Efficacy, and Safety of Potential Therapeutics: A Narrative Overview of the Complex Life of COVID-19. 2021 , 18,	5
154	In silico investigation of saponins and tannins as potential inhibitors of SARS-CoV-2 main protease (M). 2021 , 9, 9	15
153	An update of coronavirus disease 2019 (COVID-19): an essential brief. 2021 , 4, 19-38	
152	Perspective Adjunctive Therapies for COVID-19: Beyond Antiviral Therapy. 2021 , 18, 314-324	11
151	A rapid review of recent advances in diagnosis, treatment and vaccination for COVID-19. 2021 , 8, 137-153	22
150	Computational Intelligence in Drug Repurposing for COVID-19. 2021 , 273-294	3
149	COVID-19: Hard Road to Find Integrated Computational Drug and Repurposing Pipeline. 2021 , 295-309	4
148	SARS CoV-2: a review of current treatment regimens. 2020 , 5,	1
147	Knowledge, attitude, and practices of Community pharmacists about COVID-19: A cross-sectional survey in two provinces of Pakistan.	1
146	Prevalence, clinical characteristics and treatment outcomes of HIV and SARS-CoV-2 co-infection: a systematic review and meta-analysis.	1
145	CETSA-MS profiling for a comparative assessment of FDA approved antivirals repurposed for COVID-19 therapy identifies Trip13 as a Remdesivir off-target.	1
144	A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent in vitro. 2020 ,	4
143	Mucin signature as a potential tool to predict susceptibility to COVID-19. 2021 , 9, e14701	13
142	Drug Repurposing for Prevention and Treatment of COVID-19: A Clinical Landscape. 2020 , 8, e121	9

141	EFFICACY AND SAFETY OF SOME ETIOTROPIC THERAPEUTIC SCHEMES FOR TREATING PATIENTS WITH NOVEL CORONAVIRUS INFECTION (COVID-19). 2020 , 8, 150-159	6
140	Therapeutic Targets and Computational Approaches on Drug Development for COVID-19. 2020 , 20, 2210-2220	11
139	Road Map to Understanding SARS-CoV-2 Clinico-Immunopathology and COVID-19 Disease Severity. 2020 , 10,	5
138	Enfermedad por coronavirus 2019 (COVID-19) y embarazo. 2020 , 18, 399-406	0
137	COVID-19 in China: From epidemiology to treatment (Review). 2020 , 20, 223	2
136	Towards a more effective strategy for COVID-19 prevention (Review). 2021 , 21, 33	2
135	An integrative look at SARS-CoV-2 (Review). 2021 , 47, 415-434	12
134	Immune-checkpoint inhibitors from cancer to COVID-19: A promising avenue for the treatment of patients with COVID-19 (Review). 2021 , 58, 145-157	32
133	Prevalence and Clinical Outcomes of Vitamin D Deficiency in COVID-19 Hospitalized Patients: A Retrospective Single-Center Analysis. 2021 , 255, 127-134	3
132	Rapid sensitive bioscreening of remdesivir in COVID-19 medication: Selective drug determination in the presence of six co-administered therapeutics. 2021 , 40, 323-333	2
131	COVID-19 treatment in children: A systematic review and meta-analysis. 2021 , 10, 3292-3302	3
130	Potential of artificial intelligence to accelerate diagnosis and drug discovery for COVID-19. 2021 , 9, e12073	1
129	COVID-19 health inequities and association with mechanical ventilation and prolonged length of stay at an urban safety-net health system in Chicago. 2021 , 16, e0258243	
128	The safety profile of favipiravir in COVID-19 patients with severe renal impairment. 2021 , e14938	2
127	Potential interactions between antineoplastic agents and medicines used to treat Covid-19. 2021 , 10781552211040494	
126	Plant Alkaloids Inhibit Membrane Fusion Mediated by Calcium and Fragments of MERS-CoV and SARS-CoV/SARS-CoV-2 Fusion Peptides. 2021 , 9,	3
125	Novel coronavirus pathogen in humans and animals: an overview on its social impact, economic impact, and potential treatments. <i>Environmental Science and Pollution Research</i> , 2021 , 28, 68071	5.1 4
124	Current knowledge about the etiopathogenesis and therapy options for COVID-19. 2020 , 49, 43-54	1

- 123 Finding disease modules for cancer and COVID-19 in gene co-expression networks with the Core&Peel method.
- 122 Novel Coronavirus: A Newly Arranged Mini-Review. **2020**, 3, 130-135
- 121 An in-silico based clinical insight on the effect of noticeable CD4 conserved residues of SARS-CoV-2 on the CD4-MHC-II interactions.
- 120 Review on COVID-19: Rise of SARS-CoV-2 Pandemic Outbreak. **2020**, 3, 103-120 2
- 119 First report of tocilizumab use in a cohort of Latin American patients hospitalized for severe COVID-19 pneumonia.
- 118 Considerations for future novel human-infecting coronavirus outbreaks. **2020**, 11, 260
- 117 Egg yolk immunoglobulin (IgY) targeting SARS-CoV-2 S1 as potential virus entry blocker. **2021**, 6
- 116 SARS-COV-2, infection, transmission, transcription, translation, proteins, and treatment: A review. **2021**, 3
- 115 Developing a Teaching and Learning Module on Pandemic Disease for Undergraduate General Biology Education. **2020**, 14, 53-67
- 114 Public adherence to precautionary measures and preventive guidelines against COVID-19 in Sudan: An application of the Health Belief Model. 0
- 113 The Predictive Value of Initial CT Scan in Patients with COVID-19. **2020**, 22,
- 112 Infecç o por SARS-CoV-2 (COVID-19) en Pediatria. **2020**, 33, 191-203
- 111 Utility of convalescent plasma for COVID-19 treatment. **2020**, 7, 166
- 110 OTOTOXICITY OF DRUGS USED IN THE TREATMENT OF COVID-19. **2020**, 10, 9-20 0
- 109 Impacts of COVID-19 pandemic on the aquatic environment associated with disinfection byproducts and pharmaceuticals. **2021**, 151409 4
- 108 SARS-CoV-2, the Tiny Creature which Scared the Globe.. 1-13
- 107 Knowledge, Attitude and Preparations Toward COVID-19 Among Dentists in Saudi Arabia: An Online Survey (Preprint). 0
- 106 Safety and efficacy of pharmacotherapy used for the management of COVID 19: A systematic review and meta-analysis of randomized control trials

105	SIGNIFICANCE OF CHLOROQUINE AND HYDROXYCHLOROQUINE USED FOR COVID-19 TREATMENT IN FORENSIC TOXICOLOGY. 2020 , 70-72	
104	Risk Assessment of Surgical Interventions Performed on Non-Infected Patients During COVID-19 Pandemic. 2020 , 12, e11682	1
103	Transmission and Pathogenesis of Coronavirus Disease (COVID-19) Outbreak. 2020 , 10, 239-241	0
102	Safety and Efficacy of Antiviral Drugs for the Treatment of Patients with SARS-CoV-2 Infection: A Systematic Review and Meta-analyses.	
101	Knowledge, attitudes and practices of COVID 19 among Medical Laboratory Professionals in Zambia.	1
100	Beneficial Properties of Bromelain.. 2021 , 13,	4
99	PBPK modelling of dexamethasone in patients with COVID-19 and liver disease.	
98	High-Throughput Virtual Screening and Validation of a SARS-CoV-2 Main Protease Noncovalent Inhibitor. 2021 ,	12
97	Races of small molecule clinical trials for the treatment of COVID-19: An up-to-date comprehensive review. 2021 ,	3
96	A Narrative Review of Existing Options for COVID-19-Specific Treatments. 2021 , 2021, 8554192	
95	Favipiravir (6-Fluoro-3-hydroxy-2-pyrazinecarboxamide) a Broad Spectrum Inhibitor of Viral RNA Polymerase in COVID-19 Treatment. 2021 , 6, 12652-12662	0
94	Pulmonary artery targeted therapy in treatment of COVID-19 related ARDS. Literature review.. 2022 , 146, 112592	4
93	Pharmaceutical compounds used in the COVID-19 pandemic: A review of their presence in water and treatment techniques for their elimination.. 2021 , 152691	7
92	The First Case of COVID-19 in South Kalimantan. 2020 , 6, 67	
91	Evidence that Maackia amurensis seed lectin (MASL) exerts pleiotropic actions on oral squamous cells to inhibit SARS-CoV-2 infection and COVID-19 disease progression. 2020 ,	1
90	Covid-19 Data Analysis of India and Future Forecasting Using FbProphet. 2021 ,	0
89	Identification of potentially anti-COVID-19 active drugs using the connectivity MAP.. 2022 , 17, e0262751	0
88	Understanding the activating mechanism of the immune system against COVID-19 by Traditional Indian Medicine: Network pharmacology approach.. 2022 , 129, 275-379	1

87	Interleukin Receptor Antagonists and Janus Kinase Inhibitors Repurposed for Treatment of COVID-19.. 2022 ,		0
86	COVID-19 drugs in aquatic systems: a review.. 2022 , 20, 1-20		4
85	Bibliometric Analysis of International Scientific Production on Pharmacologic Treatments for SARS-CoV-2/COVID-19 During 2020.. 2021 , 9, 778203		2
84	PBPK Modelling of Dexamethasone in Patients With COVID-19 and Liver Disease.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 814134	5.6	0
83	Sheet, surveillance, strategy, salvage and shield in global biodefense system to protect the public health and tackle the incoming pandemics.. 2022 , 153469		
82	Therapeutics for COVID-19 and post COVID-19 complications: An update.. 2022 , 3, 100086		13
81	Therapeutic dilemmas in addressing SARS-CoV-2 infection: Favipiravir versus Remdesivir.. 2022 , 147, 112700		7
80	Toll-Like Receptors (TLRs) as Therapeutic Targets for Treating SARS-CoV-2: An Immunobiological Perspective.. 2021 , 1352, 87-109		1
79	COVID-19 Pulmonary and Extrapulmonary Complications. 2022 , 10, 152-174		
78	Immune response and potential therapeutic strategies for the SARS-CoV-2 associated with the COVID-19 pandemic.. 2022 , 18, 1865-1877		0
77	Optimal Control of the Coronavirus Pandemic with Impacts of Implemented Control Measures. 88-98		2
76	COVID-19: A systematic review and update on prevention, diagnosis, and treatment.. 2022 , 3, e115		2
75	Treatment Outline and Clinical Outcome of Hospitalized COVID-19 Patients: Experiences from a Combined Military Hospital of Bangladesh.		
74	Anti-Influenza Virus Study of Composite Material with MIL-101(Fe)-Adsorbed Favipiravir.. <i>Molecules</i> , 2022 , 27,	4.8	1
73	Consumption Trends of Antibiotics in Brazil During the COVID-19 Pandemic.. <i>Frontiers in Pharmacology</i> , 2022 , 13, 844818	5.6	4
72	Drug interaction risk between cardioprotective drugs and drugs used in treatment of COVID-19: A evidence-based review from six databases.. <i>Diabetes and Metabolic Syndrome: Clinical Research and Reviews</i> , 2022 , 16, 102451	8.9	5
71	Evaluation of Antibacterial and Antiviral Drug Effectiveness in COVID-19 Therapy: A Data-Driven Retrospective Approach.. <i>Pathophysiology</i> , 2022 , 29, 92-105	1.8	
70	Antiviral Potential of Indian Medicinal Plants Against Influenza and SARS-CoV: A Systematic Review. <i>Natural Product Communications</i> , 2022 , 17, 1934578X2210869	0.9	2

69	Urban food prices under lockdown: evidence from Myanmar's traditional food retail sector during COVID-19. <i>Applied Economics</i> , 1-30	1.6	1
68	Coronavirus Disease 2019 and Hypertension: How Anti-Hypertensive Drugs Affect COVID-19 Medications and Vice Versa.. <i>Current Drug Safety</i> , 2022 ,	1.4	
67	Differential Co-Expression Network Analysis Reveals Key Hub-High Traffic Genes as Potential Therapeutic Targets for COVID-19 Pandemic.. <i>Frontiers in Immunology</i> , 2021 , 12, 789317	8.4	0
66	Molecular Docking Studies of Halogenated Bicyclo[4.2.0] Inositols with SARS-CoV-2 Proteins. 2021 , 11, 99-112		
65	COVID-19: The question of genetic diversity and therapeutic intervention approaches.. <i>Genetics and Molecular Biology</i> , 2021 , 44, e20200452	2	0
64	Image_1.jpeg. 2020 ,		
63	Table_1.doc. 2020 ,		
62	DataSheet1_v1.docx. 2020 ,		
61	The Effect of Exogenous Surfactant on Moderate and Severe Stages of COVID-19 Induced ARDS: the Pilot Study of a Clinical Trial.. <i>Iranian Journal of Pharmaceutical Research</i> , 2021 , 20, 553-559	1.1	
60	An insight into the molecular mechanisms of mesenchymal stem cells and their translational approaches to combat COVID-19. 2022 , 23-46		
59	Etiotropic therapy of the new coronavirus infection: expectations and realities at the beginning of 2022. Part 1. <i>Russian Family Doctor</i> , 2022 , 26, 7-14	0.1	
58	Immune-related therapeutics: an update on antiviral drugs and vaccines to tackle the COVID-19 pandemic.. <i>Osong Public Health and Research Perspectives</i> , 2022 , 13, 84-100	6.1	
57	Bacterial and Fungal Co-Infections and Superinfections in a Cohort of COVID-19 Patients: Real-Life Data from an Italian Third Level Hospital. <i>Infectious Disease Reports</i> , 2022 , 14, 372-382	0.6	2
56	Phytomedicines explored under and studies against coronavirus: An opportunity to develop traditional medicines.. <i>South African Journal of Botany</i> , 2022 ,	2.9	0
55	Frequently Used Allopathic and Traditional Medicine for COVID-19 Treatment and Feasibility of Their Integration.. <i>Chinese Journal of Integrative Medicine</i> , 2022 , 1	2.9	
54	Theoretical insights of the drug-drug interaction between favipiravir and ibuprofen: a DFT, QTAIM and drug-likeness investigation.. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022 , 1-8	3.6	0
53	Sensing and 3D printing technologies in personalized healthcare for the management of health crises, including the COVID-19 outbreak. <i>Sensors International</i> , 2022 , 100180	6.1	0
52	Evaluation of the Effects of Favipiravir Combined with Vitamin C on Alveolar Bone in Rats. <i>Journal of Evolutionary Biochemistry and Physiology</i> , 2022 , 58, 430-440	0.5	1

51	Exploring the Potential of Metal Nanoparticles as a Possible Therapeutic Adjunct for Covid-19 Infection. <i>Proceedings of the National Academy of Sciences India Section B - Biological Sciences</i> ,	1.4	0
50	A review on drug repurposing in COVID-19: from antiviral drugs to herbal alternatives. <i>Journal of Genetic Engineering and Biotechnology</i> , 2022 , 20,	3.1	1
49	Neutrophils in COVID-19: Not Innocent Bystanders. <i>Frontiers in Immunology</i> , 2022 , 13,	8.4	7
48	Vitamin C and its therapeutic potential in the management of COVID19. <i>Clinical Nutrition ESPEN</i> , 2022 ,	1.3	2
47	Hospitalized COVID-19 Patients with Severe Acute Respiratory Syndrome: A Population-Based Registry Analysis to Assess Clinical Findings, Pharmacological Treatment and Survival. <i>Medicina (Lithuania)</i> , 2022 , 58, 829	3.1	0
46	SARS-CoV-2 and Therapeutic Approaches. <i>The Open Covid Journal</i> , 2022 , 2,		
45	Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection. <i>Medicina Clínica</i> , 2022 ,	1	
44	Differences in Global Scientific Production Between New mRNA and Conventional Vaccines Against COVID-19. <i>Environmental Science and Pollution Research</i> ,	5.1	0
43	Laboratory information management system for COVID-19 non-clinical efficacy trial data. <i>Laboratory Animal Research</i> , 2022 , 38,	1.9	0
42	Significant perspectives on various viral infections targeted antiviral drugs and vaccines including COVID-19 pandemicity. <i>Molecular Biomedicine</i> , 2022 , 3,	3.1	
41	Detecting drug-drug interactions between therapies for COVID-19 and concomitant medications through the FDA adverse event reporting system. <i>Frontiers in Pharmacology</i> , 13,	5.6	0
40	Endurance of COVID 19 in Wastewater, Natural Prescription and Antiviral Medication for the Analysis of COVID 19 and its Effects on the Development of New Antiseptic Strategies. 2022 , 100010		
39	Effects of Vitamin C on the Oral-Nasal Mucosal Damage Caused by Favipiravir in Old and Young Rats. 2022 ,		0
38	Safety and sagacious use of remdesivir: Paramount focus on contemporary perspectives. 2022 , 6, 1		0
37	Inferences of actinobacterial metabolites to combat Corona virus.		0
36	A Review on Effectiveness of Plasma Therapy in Severe COVID-19 Patients. 2022 ,		0
35	Inhibition of nonstructural protein 15 of SARS-CoV-2 by golden spice: A computational insight.		2
34	Systematic review and meta-analysis of randomized controlled trials of mesenchymal stromal cells to treat coronavirus disease 2019: is it too late?. 2022 ,		2

33	Development and Validation of HPLC-DAD Method for the Determination of Favipiravir and Studying the Impact of Vitamin C on the Pharmacokinetics of COVID-19 Antiviral Drug Favipiravir. 2022 , 9, 303	0
32	Importance of Intermittent Fasting Regimens and Selection of Adequate Therapy on Inflammation and Oxidative Stress in SARS-CoV-2 Infection. 2022 , 14, 4299	0
31	Glucocorticoids and COVID-19. 2022 , 185, 106511	1
30	The effects of mouth rinsing and gargling with mouthwash containing povidone-iodine and hydrogen peroxide on the cycle threshold value of Severe Acute Respiratory Syndrome Coronavirus 2: A randomized controlled trial of asymptomatic and mildly symptomatic patients. 11, 1238	0
29	A layman approach to adopt COVID-19 appropriate behaviour and vaccination: A narrative review. 2022 , 14, 1	0
28	Computational assessment of herbal medicine-derived compounds as potential inhibitors of SARS-CoV-2 main protease. 1-12	0
27	Towards potent Covid-19 spike protein inhibitors and catecholase activity agents: Synthesis, ADME-Tox analysis and molecular docking of new 1,2,4- triazole-based molecules.	0
26	Abduction, Clinical Reasoning, and Therapeutic Strategies. 2022 , 1-23	2
25	Cardiovascular implications of the COVID-19: Management of complications and drug safety concerns. 2022 , 27, 92	0
24	Readmission to The Emergency Room and Clinical Characteristics of Patients With COVID-19: A Single-Centre Trial.	0
23	Exploration of Anti-HIV Phytocompounds against SARS-CoV-2 Main Protease: Structure-Based Screening, Molecular Simulation, ADME Analysis and Conceptual DFT Studies. 2022 , 27, 8288	1
22	An Overview of Repurposed Drugs for Potential COVID-19 Treatment. 2022 , 11, 1678	0
21	Molecular Dynamics and Structural Studies of Zinc Chloroquine Complexes.	0
20	Mechanistic investigation of SARS-CoV-2 main protease to accelerate design of covalent inhibitors. 2022 , 12,	1
19	Evaluation the efficacy and safety of N-acetylcysteine inhalation spray in controlling the symptoms of patients with COVID-19: An open-label randomized controlled clinical trial. 2023 , 95,	0
18	Predicting the response to methylprednisolone pulses in patients with SARS-COV-2 infection. 2022 , 159, 557-562	0
17	Establishment of multicenter COVID-19 therapeutics preclinical test system in Republic of Korea. 2023 , 102189	0
16	Post-COVID depression and its multiple factors, does Favipiravir have a protective effect? A longitudinal study of indonesia COVID-19 patients. 2022 , 17, e0279184	0

- 15 Comparison of clinical outcomes of intensive care patients with COVID-19 pneumonia receiving and not receiving tocilizumab treatment. **2023**, 5, 39-46 ○
- 14 Blood pH and COVID-19. ○
- 13 Standardising policy and technology responses in the immediate aftermath of a pandemic: a comparative and conceptual framework. **2023**, 21, ○
- 12 An emerging natural antioxidant therapy for COVID-19 infection patients: Current and future directions. ○
- 11 Abduction, Clinical Reasoning, and Therapeutic Strategies. **2023**, 443-465 ○
- 10 Drug discovery: Standing on the shoulders of giants. **2023**, 207-338 ○
- 9 Clinical and treatment factors associated with the mortality of COVID-19 patients admitted to a referral hospital in Indonesia. **2023**, 11, 100167 ○
- 8 Liver Injury in Favipiravir-Treated COVID-19 Patients: Retrospective Single-Center Cohort Study. **2023**, 8, 129 ○
- 7 Oral Pathology in the Context of COVID-19: Perspectives Based on a Compilation of Literature Data. **2020**, 48, 517-531 ○
- 6 A Comprehensive Review of Natural Flavonoids with Anti-SARS-CoV-2 Activity. **2023**, 28, 2735 ○
- 5 Learning from real world data about combinatorial treatment selection for COVID-19. 6, ○
- 4 Revisiting the COVID-19 Pandemic: An Insight into Long-Term Post-COVID Complications and Repurposing of Drugs. **2023**, 3, 494-519 ○
- 3 Satisfaction of Patients Other Than COVID-19 During the Pandemic at a Multidisciplinary Centre with COVID-19 Services. 097206342211509 ○
- 2 Severe COVID-19: Drugs and Clinical Trials. **2023**, 12, 2893 ○
- 1 Liposomal drug delivery to the lungs: a post covid-19 scenario. 1-15 ○